Get the Stockscreener App
8.02
5.94%
0.4498
Addex Therapeutics Ltd Adr stock is traded at $8.02, with a volume of 946.
It is up +5.94% in the last 24 hours and up +2.92% over the past month.
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.
See More
Previous Close:
$7.5702
Open:
$8.01
24h Volume:
946
Relative Volume:
0.13
Market Cap:
$1.48B
Revenue:
$630.00K
Net Income/Loss:
$5.72M
P/E Ratio:
-23.48
EPS:
-0.3415
Net Cash Flow:
$-6.75M
1W Performance:
-4.52%
1M Performance:
+2.92%
6M Performance:
-7.92%
1Y Performance:
-7.18%
1-Day Range:
$8.01
$8.02
1-Week Range:
$7.5702
$8.02
52-Week Range:
$6.51
$13.27
Addex Therapeutics Ltd Adr Stock (ADXN) Company Profile
Name
Addex Therapeutics Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare ADXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ADXN
Addex Therapeutics Ltd Adr
|
8.02 | 8.98M | 630.00K | 5.72M | -6.75M | -0.3415 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.32 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.47 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.98 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Addex Therapeutics Ltd Adr Stock (ADXN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
Addex Therapeutics Ltd Adr Stock (ADXN) Latest News
Addex Raises $10.0 Million In Equity Financing - Barchart.com
Addex Therapeutics Earnings Call: Strategic Gains Amid Financial Challenges - TipRanks
Addex Therapeutics Reports Strong 2024 Financial Turnaround - TipRanks
META_TITLE_SECTORS - Yahoo Finance
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149 - GlobeNewswire Inc.
Coincheck Group N.V (CNCK) produces promising results - US Post News
Are Medical Stocks Lagging ADMA Biologics (ADMA) This Year? - Yahoo Finance
Are Medical Stocks Lagging Addex Therapeutics (ADXN) This Year? - Yahoo Finance
Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Are Medical Stocks Lagging Boston Scientific (BSX) This Year? - Yahoo Finance
Drug discovery and bringing new medicine to marketthe future of AI in pharma - OutSourcing-Pharma.com
What Makes Addex Therapeutics (ADXN) a New Buy Stock - Nasdaq
Addex Stock Soars on Crucial Update From Indivior Research Deal - Nasdaq
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
LYRA Stock Quote Price and Forecast - CNN
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq
Addex Therapeutics (ADXN) Stock Rallied 62.1% on Phase 2 Study - AskTraders.com
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Addex (ADXN) Terminates Parkinson's-Related Dyskinesia Study - Nasdaq
Addex To Present At The H.C. Wainwright BIOCONNECT Virtual Conference - Barchart.com
Addex Reports Q3 2021 Financial Results And Provides Corporate Update - Barchart.com
ADXN Stock Price and Chart — SIX:ADXN - TradingView
Addex Therapeutics Ltd Adr Stock (ADXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):